Characteristic | PFS | OS | ||||||
N | HR | 95% CI | P value | N | HR | 95% CI | P value | |
Univariate Cox regression | ||||||||
CRP kinetics | 107 | 107 | ||||||
Non-responder | — | — | — | — | ||||
Responder | 0.42 | 0.25 to 0.69 | <0.001 | 0.37 | 0.21 to 0.65 | <0.001 | ||
Flare | 0.32 | 0.18 to 0.56 | <0.001 | 0.26 | 0.13 to 0.50 | <0.001 | ||
PD-L1 expression (TPS) | 72 | 72 | ||||||
PDL <50% | — | — | — | — | ||||
PDL≥50% | 0.62 | 0.35 to 1.10 | 0.10 | 0.60 | 0.32 to 1.12 | 0.11 | ||
Baseline CRP | 103 | 103 | ||||||
Baseline CRP ≤5 mg/L | — | — | — | — | ||||
Baseline CRP >5 mg/L | 1.89 | 1.09 to 3.27 | 0.024 | 1.89 | 1.01 to 3.54 | 0.047 | ||
Baseline LDH | 102 | 102 | ||||||
Baseline LDH ≤250 U/L | — | — | — | — | ||||
Baseline LDH >250 U/L | 1.97 | 1.25 to 3.10 | 0.004 | 1.92 | 1.16 to 3.20 | 0.011 | ||
Baseline NLR | 103 | 103 | ||||||
Baseline NLR ≤4.7 | — | — | — | — | ||||
Baseline NLR >4.7 | 1.34 | 0.86 to 2.09 | 0.2 | 1.66 | 1.00 to 2.74 | 0.049 | ||
Presence of cerebral metastasis | 104 | 104 | ||||||
No | — | — | — | — | ||||
Yes | 2.13 | 1.35 to 3.36 | 0.001 | 2.39 | 1.45 to 3.93 | <0.001 | ||
Multivariate Cox regression | ||||||||
CRP kinetics | 91 | 91 | ||||||
Non-responder | — | — | — | — | ||||
Responder | 0.20 | 0.10 to 0.39 | <0.001 | 0.20 | 0.10 to 0.42 | <0.001 | ||
Flare | 0.27 | 0.14 to 0.52 | <0.001 | 0.22 | 0.10 to 0.48 | <0.001 | ||
Baseline CRP | 91 | 91 | ||||||
Baseline CRP ≤5 mg/L | — | — | — | — | ||||
Baseline CRP >5 mg/L | 2.03 | 1.04 to 3.97 | 0.038 | 1.91 | 0.91 to 4.01 | 0.088 | ||
Baseline LDH | 91 | 91 | ||||||
Baseline LDH ≤250 U/L | — | — | — | — | ||||
Baseline LDH >250 U/L | 2.93 | 1.68 to 5.11 | <0.001 | 2.38 | 1.34 to 4.24 | 0.003 | ||
Baseline NLR | 91 | 91 | ||||||
Baseline NLR ≤4.7 | — | — | — | — | ||||
Baseline NLR >4.7 | 0.85 | 0.50 to 1.44 | 0.5 | 1.43 | 0.78 to 2.59 | 0.2 | ||
Presence of cerebral metastasis | 91 | 91 | ||||||
No | — | — | — | — | ||||
Yes | 1.45 | 0.88 to 2.40 | 0.15 | 1.47 | 0.85 to 2.55 | 0.2 |
CRP, C reactive protein; IMIT, immune monitoring of immune therapy; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; TPS, tumor proportion score.